Zydus Lifesciences Limited ZYDUSLIFE NSEPHARMA
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopaedic surgery, including pathologies affecting the hip and knee. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 16.5% over 5 years.
- Profit CAGR of 37.0% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 8 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
| 9 | MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA | 965.10 | 65.34 | ₹93,927.75 Cr | 0.16% | 12.70% | 14.33% | 23.10% | 9.34% |
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 5,123.50 Cr | 6,290.20 Cr | 6,467.00 Cr | 6,780.40 Cr | 7,434.40 Cr |
| Cost of Revenue | - | 1,583.40 Cr | 1,697.10 Cr | 1,789.50 Cr | 1,836.30 Cr | 1,976.30 Cr |
| Gross Profit | - | 3,540.10 Cr | 4,593.10 Cr | 4,677.50 Cr | 4,944.10 Cr | 5,458.10 Cr |
| Operating Expenses | - | 2,564.10 Cr | 2,666.10 Cr | 2,884.20 Cr | 3,651.70 Cr | 4,057.00 Cr |
| Operating Income | - | 976.00 Cr | 1,927.00 Cr | 1,793.30 Cr | 1,292.40 Cr | 1,401.10 Cr |
| EBITDA | - | 1,445.10 Cr | 1,986.50 Cr | 2,243.40 Cr | 1,842.90 Cr | 2,291.10 Cr |
| Interest Expense | - | 32.00 Cr | 76.60 Cr | 84.70 Cr | 129.90 Cr | 123.00 Cr |
| Pretax Income | - | 1,184.10 Cr | 1,672.00 Cr | 1,920.60 Cr | 1,353.40 Cr | 1,659.70 Cr |
| Tax Provision | - | 179.50 Cr | 423.20 Cr | 434.00 Cr | 388.30 Cr | 318.40 Cr |
| Net Income | - | 1,023.50 Cr | 1,170.90 Cr | 1,466.80 Cr | 1,042.10 Cr | 1,272.50 Cr |
| Diluted EPS | - | 10.17 | 11.64 | 14.58 | 10.36 | 12.65 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 16,877.80 Cr | 19,021.50 Cr | 22,573.80 Cr | 26,719.70 Cr |
| Cost of Revenue | - | 6,558.90 Cr | 6,500.40 Cr | 6,338.00 Cr | 7,292.60 Cr |
| Gross Profit | - | 10,318.90 Cr | 12,521.10 Cr | 16,235.80 Cr | 19,427.10 Cr |
| Operating Expenses | - | 7,466.10 Cr | 7,981.90 Cr | 10,256.50 Cr | 13,640.50 Cr |
| Operating Income | - | 2,852.80 Cr | 4,539.20 Cr | 5,979.30 Cr | 5,786.60 Cr |
| EBITDA | - | 3,437.90 Cr | 5,617.00 Cr | 7,108.40 Cr | 8,468.00 Cr |
| Interest Expense | - | 125.50 Cr | 44.00 Cr | 165.90 Cr | 438.90 Cr |
| Pretax Income | - | 2,589.70 Cr | 4,808.90 Cr | 6,026.70 Cr | 6,621.10 Cr |
| Tax Provision | - | 587.80 Cr | 977.50 Cr | 1,411.90 Cr | 1,594.70 Cr |
| Net Income | - | 1,960.30 Cr | 3,859.50 Cr | 4,525.50 Cr | 5,040.00 Cr |
| Diluted EPS | - | 19.30 | 38.14 | 44.97 | 50.09 |
Compounded Sales Growth
| 5 Years: | 16.55% |
| 1 Year: | 16.20% |
Compounded Profit Growth
| 5 Years: | 36.99% |
| 1 Year: | 8.70% |
Stock Price Performance
| 1 Year: | +17.87% |
| 6 Months: | +16.30% |
| 3 Months: | +18.70% |
| 1 Month: | +18.32% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 25,756.40 Cr | 29,280.80 Cr | 37,201.70 Cr | 52,406.60 Cr |
| Current Assets | - | 10,016.40 Cr | 11,501.40 Cr | 17,046.10 Cr | 19,906.10 Cr |
| Cash & Equivalents | - | 487.80 Cr | 413.00 Cr | 826.80 Cr | 855.20 Cr |
| Inventory | - | 3,413.30 Cr | 3,441.90 Cr | 3,944.00 Cr | 5,628.10 Cr |
| Receivables | - | 4,416.80 Cr | 5,220.20 Cr | 4,024.70 Cr | 5,415.70 Cr |
| Total Liabilities | - | 6,068.10 Cr | 7,179.20 Cr | 10,843.30 Cr | 22,824.40 Cr |
| Current Liabilities | - | 5,530.70 Cr | 5,341.90 Cr | 9,041.60 Cr | 15,711.90 Cr |
| Long Term Debt | 362.10 Cr | 0 | 0 | - | 3,188.00 Cr |
| Total Debt | - | 1,194.90 Cr | 804.20 Cr | 3,213.20 Cr | 12,496.00 Cr |
| Total Equity | - | 17,515.80 Cr | 19,829.50 Cr | 23,953.10 Cr | 27,111.40 Cr |
| Shares Outstanding | - | 101.22 Cr | 100.62 Cr | 100.62 Cr | 100.62 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 2,688.80 Cr | 3,196.30 Cr | 6,781.10 Cr | 2,116.60 Cr |
| Investing Cash Flow | - | 1,535.00 Cr | -1,475.20 Cr | -8,357.80 Cr | -8,296.10 Cr |
| Financing Cash Flow | - | -4,400.40 Cr | -1,778.80 Cr | 1,995.30 Cr | 5,806.90 Cr |
| Capital Expenditure | - | -1,030.90 Cr | -906.60 Cr | -1,693.70 Cr | -2,671.50 Cr |
| Free Cash Flow | - | 1,657.90 Cr | 2,289.70 Cr | 5,087.40 Cr | -554.90 Cr |
| Net Change in Cash | - | -176.60 Cr | -57.70 Cr | 418.60 Cr | -372.60 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 61.1% | 65.8% | 71.9% | 72.7% |
| Operating Margin % | - | 16.9% | 23.9% | 26.5% | 21.7% |
| Net Margin % | - | 11.6% | 20.3% | 20.0% | 18.9% |
| ROE % | - | 11.2% | 19.5% | 18.9% | 18.6% |
| ROCE % | - | 14.1% | 19.0% | 21.2% | 15.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ZYDUSLIFE